Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective
Moderna Inc said it will request authorization for emergency use in the United States and the European Union of its COVID-19 vaccine on Monday, based on the full results of the latest phase of a study that showed that their vaccine is 94.1% effective, without serious safety concerns.
Moderna also reported an efficacy rate consistent with race, age, ethnicity, and gender and indicated that its vaccine was 100% capable of preventing severe symptoms from COVID-19, the disease that has killed 1, 5 million people in the world.
The procedure will leave Moderna as the second company in line to receive authorization for the emergency use of its vaccine this year in the United States, after the formula developed by Pfizer (NYSE: PFE ) and BioNTech will be 95% effective. in clinical trials.
“We thought we had a highly effective vaccine. Now we have the data to prove it,” Ral Zaks, the firm’s chief medical officer, said in a telephone interview. “We hope to play an important role in defeating this pandemic.”
Zaks said he was excited to see the 94.1% result over the weekend: “It’s the first time I’ve allowed myself to cry. With this level of effectiveness, when you do the math on what this means for the pandemic that It surrounds us, it’s just overwhelming. “
Of the 196 volunteers who became infected with COVID-19 in the trial with more than 300,000 people, 185 had received a placebo and only 11 the vaccine. Moderna reported 30 severe cases of the coronavirus – all in the placebo group – which means that the formula is 100% effective in preventing severe symptoms of COVID-19.
“As the numbers of coronavirus in the world increase, so is confidence in the incredible level of protection that a product can offer to the population,” said Alexander Edwards, associate professor of biomedical technology at the University of Reading in the United Kingdom. .
In addition to the application in the United States, Moderna will request conditional approval for its vaccine from the European Medicines Agency (EMA), which has already begun to review the data. The company said it would also contact other health regulators.
Pfizer has already requested approval for emergency use of its vaccine in the United States and Europe, which is one week ahead of Moderna.
Moderna said it was on track to have about 20 million doses of its vaccine ready for distribution in the United States by the end of 2020, enough to inoculate 10 million people.